245 related articles for article (PubMed ID: 16091471)
1. NKG2D-independent suppression of T cell proliferation by H60 and MICA.
Kriegeskorte AK; Gebhardt FE; Porcellini S; Schiemann M; Stemberger C; Franz TJ; Huster KM; Carayannopoulos LN; Yokoyama WM; Colonna M; Siccardi AG; Bauer S; Busch DH
Proc Natl Acad Sci U S A; 2005 Aug; 102(33):11805-10. PubMed ID: 16091471
[TBL] [Abstract][Full Text] [Related]
2. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity.
Diefenbach A; Jensen ER; Jamieson AM; Raulet DH
Nature; 2001 Sep; 413(6852):165-71. PubMed ID: 11557981
[TBL] [Abstract][Full Text] [Related]
3. Molecular competition for NKG2D: H60 and RAE1 compete unequally for NKG2D with dominance of H60.
O'Callaghan CA; Cerwenka A; Willcox BE; Lanier LL; Bjorkman PJ
Immunity; 2001 Aug; 15(2):201-11. PubMed ID: 11520456
[TBL] [Abstract][Full Text] [Related]
4. IFN-dependent down-regulation of the NKG2D ligand H60 on tumors.
Bui JD; Carayannopoulos LN; Lanier LL; Yokoyama WM; Schreiber RD
J Immunol; 2006 Jan; 176(2):905-13. PubMed ID: 16393975
[TBL] [Abstract][Full Text] [Related]
5. A novel ligand for the NKG2D receptor activates NK cells and macrophages and induces tumor immunity.
Diefenbach A; Hsia JK; Hsiung MY; Raulet DH
Eur J Immunol; 2003 Feb; 33(2):381-91. PubMed ID: 12645935
[TBL] [Abstract][Full Text] [Related]
6. EAE tolerance induction with Hsp70-peptide complexes depends on H60 and NKG2D activity.
Galazka G; Jurewicz A; Orlowski W; Stasiolek M; Brosnan CF; Raine CS; Selmaj K
J Immunol; 2007 Oct; 179(7):4503-12. PubMed ID: 17878346
[TBL] [Abstract][Full Text] [Related]
7. The herpesviral Fc receptor fcr-1 down-regulates the NKG2D ligands MULT-1 and H60.
Lenac T; Budt M; Arapovic J; Hasan M; Zimmermann A; Simic H; Krmpotic A; Messerle M; Ruzsics Z; Koszinowski UH; Hengel H; Jonjic S
J Exp Med; 2006 Aug; 203(8):1843-50. PubMed ID: 16831899
[TBL] [Abstract][Full Text] [Related]
8. Cutting edge: the minor histocompatibility antigen H60 peptide interacts with both H-2Kb and NKG2D.
Cerwenka A; O'Callaghan CA; Hamerman JA; Yadav R; Ajayi W; Roopenian DC; Joyce S; Lanier LL
J Immunol; 2002 Apr; 168(7):3131-4. PubMed ID: 11907062
[TBL] [Abstract][Full Text] [Related]
9. Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis.
Ito Y; Kanai T; Totsuka T; Okamoto R; Tsuchiya K; Nemoto Y; Yoshioka A; Tomita T; Nagaishi T; Sakamoto N; Sakanishi T; Okumura K; Yagita H; Watanabe M
Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G199-207. PubMed ID: 17962357
[TBL] [Abstract][Full Text] [Related]
10. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions.
Allez M; Tieng V; Nakazawa A; Treton X; Pacault V; Dulphy N; Caillat-Zucman S; Paul P; Gornet JM; Douay C; Ravet S; Tamouza R; Charron D; Lémann M; Mayer L; Toubert A
Gastroenterology; 2007 Jun; 132(7):2346-58. PubMed ID: 17570210
[TBL] [Abstract][Full Text] [Related]
11. Two novel NKG2D ligands of the mouse H60 family with differential expression patterns and binding affinities to NKG2D.
Takada A; Yoshida S; Kajikawa M; Miyatake Y; Tomaru U; Sakai M; Chiba H; Maenaka K; Kohda D; Fugo K; Kasahara M
J Immunol; 2008 Feb; 180(3):1678-85. PubMed ID: 18209064
[TBL] [Abstract][Full Text] [Related]
12. Selective down-regulation of the NKG2D ligand H60 by mouse cytomegalovirus m155 glycoprotein.
Hasan M; Krmpotic A; Ruzsics Z; Bubic I; Lenac T; Halenius A; Loewendorf A; Messerle M; Hengel H; Jonjic S; Koszinowski UH
J Virol; 2005 Mar; 79(5):2920-30. PubMed ID: 15709011
[TBL] [Abstract][Full Text] [Related]
13. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
14. Ligands for murine NKG2D display heterogeneous binding behavior.
Carayannopoulos LN; Naidenko OV; Kinder J; Ho EL; Fremont DH; Yokoyama W
Eur J Immunol; 2002 Mar; 32(3):597-605. PubMed ID: 11857333
[TBL] [Abstract][Full Text] [Related]
15. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo.
Wiemann K; Mittrücker HW; Feger U; Welte SA; Yokoyama WM; Spies T; Rammensee HG; Steinle A
J Immunol; 2005 Jul; 175(2):720-9. PubMed ID: 16002667
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
17. Strategies for target cell recognition by natural killer cells.
Diefenbach A; Raulet DH
Immunol Rev; 2001 Jun; 181():170-84. PubMed ID: 11513138
[TBL] [Abstract][Full Text] [Related]
18. T cells gene-engineered with DAP12 mediate effector function in an NKG2D-dependent and major histocompatibility complex-independent manner.
Teng MW; Kershaw MH; Hayakawa Y; Cerutti L; Jane SM; Darcy PK; Smyth MJ
J Biol Chem; 2005 Nov; 280(46):38235-41. PubMed ID: 16169855
[TBL] [Abstract][Full Text] [Related]
19. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism.
Takaki R; Hayakawa Y; Nelson A; Sivakumar PV; Hughes S; Smyth MJ; Lanier LL
J Immunol; 2005 Aug; 175(4):2167-73. PubMed ID: 16081783
[TBL] [Abstract][Full Text] [Related]
20. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer S; Groh V; Wu J; Steinle A; Phillips JH; Lanier LL; Spies T
Science; 1999 Jul; 285(5428):727-9. PubMed ID: 10426993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
